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RIPping the Skin Apart: Necroptosis
Signaling in Toxic Epidermal
Necrolysis
Diana Panayotova-Dimitrova1, Maria Feoktistova1 and
Martin Leverkus1,2,3
Toxic epidermal necrolysis (TEN) is a rare but potentially fatal drug hyper-
sensitivity reaction. Although a number of pathophysiological hints have been
identiﬁed over the past decade, details of the effector mechanisms within the
skin remain obscure. A novel study by Kim et al. now sheds light on its
pathophysiology. The investigators demonstrate convincingly that receptor-
interacting kinase 3 (RIPK3) levels are upregulated substantially in the lesional
skin of patients with TEN and that this is followed by the generation of reactive
oxygen species, activation of mixed lineage kinase-like protein, and subsequent
necroptotic cell death of keratinocytes. These data suggest that therapies that
interfere with RIPK3 activation and necroptosis induction could beneﬁt patients
with TEN.
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Toxic epidermal necrolysis (TEN) is a
severe adverse drug reaction of the skin
and mucous membranes. Its name was
ﬁrst coined by Allan Lyell, (1956). TEN is
a rare disease, with incidence rates of
about 0.4–1.2 cases per million per
year. As TEN has a mortality rate of up
to 30%, depending on the extent
of skin involvement and comorbidities
(Schwartz et al., 2013), the disease can
be classiﬁed as true dermatological
emergency. An efﬁcient treatment for
TEN is lacking to date, and randomized
clinical trials are difﬁcult to conduct
because of its obscure pathophysiology
and its overall rare incidence. Thus,
additional mechanistic insights into the
molecular mechanism leading to the
pathology of TEN are imperative and a
prerequisite for more effective treatment.
Hypotheses for TEN pathophysiology
include genetic predisposition com-
bined with HLA determinants (Roujeau
et al., 1987). It is based on a direct inter-
action of speciﬁc HLA haplotypes and
certain drugs such as carbamazepine,
abacavir, or nevirapine (for review see
Wei et al., 2012). The initiating phase
of cell death is attributed to interactions
between HLA determinants, drug epi-
topes, and T-cell receptors (TCRs) of, as
yet, poorly characterized T-cell subsets.
This results in unwanted immune cell
activation. Ultimately, fulminant kerati-
nocyte cell death and extensive
epidermal detachment represent the
effector phase and the ﬁnal conse-
quence of the hypersensitivity response.
Cytotoxic immune cells and/or soluble
factors such as granulysin, CD95L,
annexin A1, and micro RNA 18a-5p
regulation have been suggested as caus-
ing keratinocyte death (Viard et al., 1998;
Chung et al., 2008; Chung and Hung,
2012; Ichihara et al., 2014; Saito et al.,
2014). Interestingly, both of the major
forms of cell death, apoptosis and
necrosis, appear to have roles. Classical
apoptosis and the more recently
described programed necrosis (in case
of involvement of receptor-interacting
protein (RIP) kinases (RIPKs) also called
necroptosis) have been proposed as
relevant cell death pathways responsible
for the extensive keratinocyte cell
death that is seen in TEN. For example,
upregulation of CD95 ligand (CD95L)
expression in keratinocytes in TEN has
been suggested as causative (Viard et al.,
1998). CD95L is one of the key players in
the receptor-induced cell death signaling
pathway. Stimulation of death receptors
(DRs) on the cell surface results in
initiation of a proteolytic cascade that
culminates in the activation of effector
caspases, which are the mediators of
apoptosis. In order to avoid uncontrolled
apoptosis, a number of antiapoptotic
proteins control the cascade at several
different levels. The cellular FLICE-like
inhibitory protein (cFLIP) is one inhibitor
of extrinsic cell death. Epidermal loss of
cFLIP was recently suggested as a possi-
ble prerequisite for epidermal cell death
in TEN, as a mouse model with skin-
speciﬁc inducible deﬁciency of cFLIP
showed a phenotype resembled typical
TEN morphology. This effect was shown
to be reduced by blocking tumor necrosis
factor (TNF) signaling (Panayotova-
Dimitrova et al., 2013), suggesting TNF
as an additional player in TEN. In
accordance with these data, a recent
study reported that early blockade of TNF
signaling by TNF receptor 2-Fc resulted in
complete healing of 10 TEN patients
(Paradisi et al., 2014). These ﬁndings
suggest an important role for TNF-
dependent cell death in TEN, and it
suggests TNF inhibitors as potential treat-
ment options.
TEN: lessons learned from the loss of cell
death resistance in the skin
Recent reports have indicated that the
alternative death mode, programed
necrosis or necroptosis, may contribute
to the pathogenesis of TEN. It has been
suggested that interaction of soluble
annexin 1 with its receptor contri-
butes to TEN (Saito et al., 2014). Both
apoptotic and necrotic cell death are
regulated in part by overlapping mole-
cular machineries. The Ripoptosome, a
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complex described in 2011 (Feoktistova
et al., 2011; Tenev et al., 2011), has
been shown to participate in both
apoptosis and necroptosis. RIPK1 and
RIPK3 were described as core mole-
cules in the ripoptosome. RIPK3 is a
downstream target of RIPK1, forming a
complex, which may or may not
contain RIPK1. Activated RIPK3 gains
the ability to phosphorylate and activate
mixed lineage kinase domain-like pro-
tein(MLKL; Murphy et al., 2013).
Phosphorylated MLKL molecules form
homooligomers, which form pores and
disrupt membrane integrity, ﬁnally
resulting in cell death (Wang et al.,
2014) The core molecular complex of
RIPK1 and RIPK3 has long been
recognized as the necrosome (Vanden
Berghe et al., 2014). How to retain the
proper quality and quantity of cell death
in keratinocytes during the progression
of TEN is thus an important question.
Most likely the mystery of TEN (and
keratinocyte) progression will only be
answered by detailed studies and new
understanding of the intracellular death
cascades in this cell type, but success
in this effort may be rewarded by
innovative therapeutic options that
target the loss of cell death resistance
in the skin.
RIPK: a potential target to interfere with
the deadly effector phase of TEN?
In the current issue of the JID, Kim
et al. (2015) shed new light on the
pathophysiology of TEN. They investi-
gated the molecular machinery govern-
ing the execution phase of programed
necrosis or more speciﬁcally necrop-
tosis. As convincingly shown in the
paper, it is the necroptosis effector
cascade RIPK3, but not MLKL, that is a
potential bottleneck to prevent
necroptosis in primary keratinocytes,
as evidenced by its strong induction in
TEN lesions in vivo. At the functional
level, the authors show that the BRAF
inhibitor Dabrafenib is, surprisingly, a
potent inhibitor of RIPK3, based on its
full inhibition of MLKL phosphorylation.
This indicates a potential therapeutic
avenue for RIPK3 inhibitors (Figure 1).
Kim et al. (2015) ﬁrst analyzed histo-
logically the expression of two impor-
tant proteins required for necroptosis in
patients withf TEN. Even though their
results partially contradict data from
another study, which showed variable
expression levels of MLKL and RIPK3 in
keratinocyte protein lysates isolated
from TEN patients (Saito et al., 2014),
Kim et al. (2015) show convincingly
that, in the epidermis of lesional skin,
the expression of RIPK3 is strongly and
signiﬁcantly upregulated. Importantly,
this upregulation was demonstrated to
result in increased levels of phos-
phorylated MLKL in situ. To investigate
further the possible role of RIPK3
further, Kim et al. (2015) analyzed the
potential of this molecule to modulate
the sensitivity to cell death signals in
different keratinocyte cell lines. In their
in vitro system Kim et al. (2015) choose
the nitric oxide (NO) donor sodium
nitro prusside (SNP) as a modulator of
cell survival and death. It had been
demonstrated previously that upregu-
lation of inducible NO is associated
with TEN (Viard-Leveugle et al., 2013).
Kim et al. (2015) now conﬁrmed
the signiﬁcance of RIPK3-dependent
necroptosis for SNP-induced keratino-
cyte cell death. They compared dif-
ferent pharmacological inhibitors of
necroptosis, such as necrostatin-1,
Dabrafenib, and necrosulfonamide,
and they compared these compounds
with the “classical” apoptosis inhibitor,
the pharmacological caspase inhibitor
zVAD-fmk. They showed in conclusive
functional experiments that com-
bined pretreatment with these inhibitors
resulted in much better protection from
SNP-induced cell death when com-
pared with zVAD-fmk alone. Further-
more, when the expression level of
RIPK3 was altered by knockdown of
RIPK3 or MLKL, they observed inhibi-
tion of SNP-induced cell death, accom-
panied by lowered induction of the
stress kinases c-Jun N-terminal kinase
(JNK) and p38 activation. Accordingly,
RIPK3 overexpressing cells showed
increased sensitivity to SNP-mediated
cell death, as well as higher levels of
JNK and p38 activation. Conﬁrming
their in situ ﬁndings, Kim et al. (2015)
then also demonstrated that MLKL
activation is associated with the RIPK3
expression level. Taken together, the
study gives important hints about
the signiﬁcance of necroptotic cell
death signaling in the pathogenesis of
TEN. The elevated RIPK3 expression
in the epidermis of TEN, which is
accompanied by the induction of
MLKL phosphorylation, gives strong
relevance to this pathway during TEN.
The study thus highlights that RIPK3 is a
potential target for drug development in
treating TEN, as RIPK3 inhibitors, as a
novel class of kinase inhibitors, are
currently under preclinical develop-
ment (Mandal et al., 2014).
Beyond drug development the study
by Kim et al. (2015) raises a number
of intriguing questions regarding the
mechanistic control of RIPK3-depen-
dent cell death in TEN. For example,
Clinical Implications
● Toxic epidermal necrolysis (TEN) is a rare but life-threatening drug
hypersensitivity reaction with a sudden, and to date largely unexplained,
loss of cell death resistance in the epidermis.
● The study by Kim et al. reveals that the receptor-interacting kinase 3
(RIPK3) is highly induced in the epidermis of lesional skin of patients
with TEN.
● RIPK3 overexpression in TEN correlates with in situ activation of the major
necroptosis effector, mixed lineage kinase like (MLKL).
● The data suggest that not only effectors of apoptosis such as caspases but
also the major effectors of necroptosis contribute to epidermal cell death
in TEN.
● Targeting of the necroptosis machinery using RIPK3 inhibitors, currently
under preclinical development, may prove beneﬁcial for patients
with TEN.
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it would be interesting to understand in
greater detail the role of MLKL, and
whether RIPK3’s sole substrate in kera-
tinocytes is MLKL. The interesting ﬁnd-
ing that RIPK3 expression impacts on
the constant activation of JNK and p38
hints to additional targets of RIPK3
beyond MLKL. Understanding this inter-
play of necroptosis signaling with
inﬂammatory signal transduction
pathways, such as JNK and p38, but
also inﬂammasome-controlled signaling
pathways, as recently reported (Gurung
et al., 2014; Lawlor et al., 2015), will
certainly facilitate understanding how
the epidermis is killed during TEN
(Figure 1). Finally, the experiments
shown in the paper raise the hypothesis
that NO not only has the ability to
induce TNF expression but that it may
impact on NF-κB activity in the skin,
which is critical during the progression
of TEN (Figures 1 and 2). Because TNF
is an important player in TEN pathology
(Paquet et al., 1994; Panayotova-
Dimitrova et al., 2013; Paradisi et al.,
2014), additional analyses of the ability
of SNP to induce TNF itself should be
useful. Experimentally, this may be
addressed by experiments that interfere
functionally with TNF signaling (e.g.,
with TNF-R2-Fc fusion proteins or
blocking antibodies) whenever NO is
induced in keratinocytes.
Altogether, it is obvious that the
inability of TEN keratinocytes to main-
tain intrinsic cell death resistance is
regulated in a complex manner. Might
there be alternative intracellular cell
death inhibitors other than cFLIP that
are needed to inhibit keratinocytes from
cell death? Other candidates as cell
death regulators may be involved in the
rapid epidermal destruction that occurs
in patients with TEN (Figure 2). For
example, the role of inhibitor of apop-
tosis proteins (IAPs), potent inhibitors of
necroptosis, during TEN is unknown.
Loss of cIAPs, in line with the data from
Kim et al. (2015), unleashes the ability
of RIP kinases to kill by necroptosis
execution. Thus, cIAP modulation, as
exempliﬁed by studies with IAP
antagonists by Kim et al. (2015), may
represent an additional strike against
cell death resistance in TEN keratino-
cytes. Furthermore, as NF-κB is a
major protector from TNF-mediated cell
death, it will also be interesting
to determine whether transcriptional
NF-κB activity is lost in the skin of
patients with TEN. Unquestionably,
further detailed experimental studies
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Figure 1. Important effector pathways of cell death in the epidermis and during toxic epidermal necrolysis (TEN). Upon activation of death receptors, such as
tumor necrosis factor (TNF-R), a membrane-bound molecular complex (complex I) is formed on the platform of the death domain of TNF-R1. This leads
subsequently to the formation of a cytoplasmic complex II (or a Ripoptosome under inhibitor of apoptosis protein (IAP)-depleted conditions). The formation and
function of this complex is prevented by cIAP1 and cIAP2. Both IAPs ubiquitinate receptor-interacting kinase 1 (RIPK1). Loss of cIAPs by the use of SMAC
mimetics, or loss of cFLIP (a highly CHX sensitive protein), sensitizes keratinocytes to cell death. Abrogation of cell death resistance by loss of these proteins
is achieved by several pathways. cFLIP isoforms either partially or completely block complex formation, as well as caspase activation within the TNF complex II.
Complex II (or the Ripoptosome) can induce caspase activation (blocked by zVAD-fmk) or can favor formation of the Necrosome, a complex of RIPK1 and
RIPK3. The necrosome activates RIPK3 by RIPK1 (blocked by Necrostatin-1) and is followed by mixed lineage kinase-like (MLKL) activation (blocked by
Dabrafenib). Activated MLKL lastly oligomerizes and translocates to plasma membranes (blocked by necrosulfonamide (NSA)), ultimately leading to necroptosis.
Both apoptosis and necroptosis contribute to TEN as shown by Kim et al. (2015). JNK, c-Jun N-terminal kinase.
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that investigate the breakdown of cell-
intrinsic survival mechanism in TEN
keratinocytes will clarify which mole-
cules could be employed for future
drug development. Most likely, and
as suggested by Kim et al. (2015),
combination therapies that target not
only apoptosis but also necroptotic cell
death will achieve better disease control
of TEN and could prevent the skin from
being “RIPped apart”.
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Figure 2. Important roadblocks needed to maintain cell death resistance in keratinocytes in vivo. Upon
drug intake, in the presence of genetic predisposition and a certain T-cell receptor (TCR) range, a poorly
deﬁned immune reaction is activated. Immune cells inﬁltrate the skin and cell death resistance in
epidermal keratinocytes brakes down, resulting in massive cell death and denudation of the epidermis in
toxic epidermal necrolysis (TEN) patients. In addition to cFLIP, other important cell death regulators
in keratinocytes, such as NF-κB and inhibitor of apoptosis protein (cIAP), may also be regulated
during TEN. TNF, tumor necrosis factor.
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